Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group

J. D. Lundgren, A. N. Phillips, C. Pedersen, N. Clumeck, J. M. Gatell, A. M. Johnson, B. Ledergerber, S. Vella and J. O. Nielsen
Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark.

OBJECTIVE--To determine the association between elapsed time since starting zidovudine and survival in patients with acquired immunodeficiency syndrome (AIDS). DESIGN--Inception cohort and observational study of patients treated and not treated with zidovudine. SETTING--Fifty-one centers in 17 European countries. PATIENTS--A total of 4484 patients diagnosed as having AIDS from 1979 to 1989 who survived their initial AIDS-defining event and who had not started zidovudine before AIDS diagnosis. MAIN OUTCOME MEASURES--Use of zidovudine and mortality. RESULTS--Among patients who did not receive zidovudine, the death rate was approximately constant for the first 5 years after AIDS diagnosis. For patients treated with zidovudine, the death rate within the first year since starting zidovudine was markedly lower than for untreated patients who had developed AIDS at the same time (relative rate, 0.47; 95% confidence interval [CI], 0.42 to 0.51). For longer times since starting zidovudine, the association with reduced mortality rate was diminished, and for patients surviving more than 2 years since starting zidovudine, the death rate was greater than for untreated patients who had developed AIDS at the same time (relative rate, 1.35; 95% CI, 1.15 to 1.58). Adjustment for other prognostic factors failed to substantially affect this observation. CONCLUSIONS--When initiated after the time of AIDS diagnosis, zidovudine was associated with improved prognosis but for no more than 2 years after starting therapy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid
Kahn et al.
Am. J. Public Health 2001;91:1464-1473.
ABSTRACT | FULL TEXT  

Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy
KIRK et al.
Am. J. Respir. Crit. Care Med. 2000;162:865-872.
ABSTRACT | FULL TEXT  

Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996
Schwarcz et al.
Am J Epidemiol 2000;152:178-185.
ABSTRACT | FULL TEXT  

Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival
Kitahata et al.
NEJM 1996;334:701-707.
ABSTRACT | FULL TEXT  

Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease
Chaisson et al.
NEJM 1995;333:751-756.
ABSTRACT | FULL TEXT  

Knowledge of Drugs for Myocardial Infarction: Generalists versus Specialists
Barry et al.
NEJM 1995;332:472-474.
FULL TEXT  

Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection
Phillips et al.
BMJ 1994;309:309-313.
ABSTRACT | FULL TEXT  

Slow Progress -- but Progress -- against HIV
Journal Watch Dermatology 1994;1994:15-15.
FULL TEXT  

SLOW PROGRESS -- BUT PROGRESS -- AGAINST HIV
JWatch General 1994;1994:2-2.
FULL TEXT